Literature DB >> 29131905

High Costs of FDA Approval for Formerly Unapproved Marketed Drugs.

Aaron Hakim1, Ravi Gupta2, Joseph S Ross3,4.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 29131905     DOI: 10.1001/jama.2017.16481

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  1 in total

1.  The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs.

Authors:  Liam Bendicksen; Aaron S Kesselheim; Benjamin N Rome
Journal:  Chest       Date:  2022-08       Impact factor: 10.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.